Just Earth News | @justearthnews | 18 Dec 2021, 08:14 am Print
Pfizer-AstraZeneca Vaccines Image: Pixabay
Geneva/UNI/Sputnik: Preliminary results of a non-peer-reviewed study from the United Kingdom indicate reduced effectiveness of the Pfizer and AstraZeneca vaccines against the Omicron coronavirus variant, the World Health Organization (WHO) has said.
In its technical brief on enhancing readiness for Omicron, published on Friday, the WHO referenced a preprint by a team of UK medical scientists, titled "Effectiveness of Covid 19 vaccines against the Omicron (B.1.1.529) variant of concern."
"Results from England indicate a significant reduction in vaccine effectiveness against symptomatic disease for Omicron compared to Delta after two vaccine doses of either Pfizer BioNTech-Comirnaty or AstraZeneca-Vaxzevria vaccines. There was, however, higher effectiveness two weeks after a Pfizer BioNTech-Comirnaty booster, which was slightly lower or comparable to that against Delta," the WHO said in the document, adding that the study also shows higher effectiveness of the Pfizer booster two weeks after.
The organization stressed that this is preliminary data and thus should be interpreted with caution.
In November, the WHO identified the new strain as one of concern, as its high number of mutations possibly makes it more transmissible and dangerous. The WHO has dubbed it Omicron, the 15th letter of the Greek alphabet.
- Over 260 million people in USA will be either obese or overweight by 2050, reveals new study
- New report shows unhealthy eating drives $8 trillion in annual hidden costs
- WHO lists 17 pathogens as top priorities for developing new vaccine
- Study finds low-sugar diet in early childhood has a connection with reducing diabetes and BP risk
- Low-sugar diet in early childhood reduces lifetime risk of chronic disease, shows new study
